Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids | Zendy

Ruth J. Pepper | Zendy; Megan Griffith | Zendy; Cliona C. Kirwan | Zendy; Jeremy Levy | Zendy; David Taube | Zendy; Charles D. Pusey | Zendy; Liz Lightstone | Zendy; Thomas Cairns | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids

Author(s) -

Ruth J. Pepper,

Megan Griffith,

Cliona C. Kirwan,

Jeremy Levy,

David Taube,

Charles D. Pusey,

Liz Lightstone,

Thomas Cairns

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp336

Subject(s) - medicine , rituximab , lupus nephritis , maintenance therapy , proteinuria , gastroenterology , cyclophosphamide , prednisolone , immunosuppression , systemic lupus erythematosus , nephritis , prednisone , surgery , urology , chemotherapy , kidney , disease , lymphoma

Lupus nephritis is a life-threatening complication of SLE. Treatment regimes include steroids and cyclophosphamide, both associated with significant morbidity. Newer regimes include mycophenolate mofetil (MMF). We report our outcomes in a prospectively monitored cohort of patients receiving our new standard treatment protocol, comprising rituximab induction therapy and MMF maintenance in patients already taking maintenance immunosuppression for SLE who developed lupus nephritis. We then attempted steroid reduction/withdrawal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research